Respiratory inhaler are sometimes used with a complementary spacer or holding chamber device, in order to reduce deposition in mouth and throat and to alleviate the need for precise synchronization of the start of inhalation with actuation of the device.

Statistics:

The global respiratory inhaler market is estimated to be valued at US$ 32,921.8 Mn in terms of value in 2019 and is expected to reach US$ 46,984.1 Mn by the end of 2027.

Global Respiratory Inhaler Market: Drivers

The increasing adoption of combination therapies such as triple combination therapy for chronic obstructive pulmonary disease (COPD) patients is expected to drive growth of the global respiratory inhaler market over the forecast period. Moreover, rising demand for combined therapies is attributed to benefits offered by combined therapies such as it is more reliable in complex patients, increased efficacy, and easy reimbursement policies related with the therapy.

Global Respiratory Inhaler Market: Opportunities

Moreover, smart inhaler technology is developed to aid patients in keeping a check on their doses and offers various other features. Some devices with smart inhaler technology have the ability to read environment pollution, in terms of air quality, and it alerts the patient about air quality, which can trigger asthma. For instance, Propeller Health, a U.S.-based company started supplementing medicines with this technology. They have connected an inhaler with Bluetooth transmitter to provide connectivity to the smartphone. This technology keeps a track of patient’s asthmatic attack frequency along with possible causes that triggers asthma and it also provide this information to their respective healthcare professional.

Request For Sample Copy Here: https://www.coherentmarketinsights.com/insight/request-sample/227

Global Respiratory Inhaler Market: Restraints

The increasing adoption of respiratory inhaler devices has resulted in high demand for pulmonologist, physicians, and nurses to enable or ensure correct usage of inhalers and nebulizers and to provide adequate training to patients. However, lack of skilled pulmonologist and physicians, especially in developing regions are expected to hamper growth of the market to some extent over the forecast period.

Key Takeaways:

Among product type, metered dose inhaler segment was valued at US$ 22,360.9 Mn in 2018 and is expected to reach US$ 33,825.0 Mn by 2027 exhibiting a CAGR of 4.5% during the forecast period.

Metered-dose inhaler delivers precise dose of medication in aerosol form. The metered-dose inhaler was the first inhaler that was marketed in 1950s and is still the most common inhaler used globally. Moreover, its low cost in comparison to other advanced inhalers such as dry powder inhaler and nebulizer, gives it a competitive advantage, especially in emerging economies such as India, China, and Brazil, where cost is one of the critical factors.

Among technology, manually operated inhaler devices segment held a dominant position in the global respiratory inhaler market in 2018, accounting for 93.1% share in terms of value, followed by digitally operated inhaler devices. Manual inhalers are the most common type of respiratory inhalers. In manual inhalers, medication is stored in pressurized canister in solution form, which also contains a propellant. The most common propellant that is used include hydrofluoroalkane (HFA), which is eco-friendly.

Among disease indication, asthma segment held a dominant position in the global respiratory inhaler market in 2018, accounting for 60.4% share in terms of value, followed by COPD and pulmonary arterial hypertension, respectively.

Moreover, key players are focusing on product launches and approvals for the treatment of asthma is expected to drive growth of the market over the forecast period. For instance, in January 2017, AstraZeneca received the U.S. FDA approval for its Symbicort (budesonide/formoterol fumarate dihydrate), a metered-dose inhaler for the treatment of asthma in pediatric patients aged 6 to 12 years.

Market Trends

In addition, market is witnessing increasing number of R&D about proper usage of inhaler device. For instance, in September 2018, researchers from University of Helsinki, Finland, reported investigation of non-verbal, demonstrational videos as a method of teaching inhaler naïve individuals on how to use a dry powder inhaler (DPI).

Moreover, there is increasing launch of devices to track usage pattern of metered-dose inhalers (MDI) by key players. For instance, in November 2019, Lupin Ltd. launched a device Adhero, which is used for tracking usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.

Get Flat USD 2000 OFF

Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2226

Reasons to Purchase this Report:

Current and future of global Cancer Registry Software Market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

Global Respiratory Inhaler Market: Competitive Landscape

Key players operating in the global respiratory inhaler market include, AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.

Global Respiratory Inhaler Market: Key Developments

Moreover, key players in the market are focused on launching smart inhaler devices to expand their product portfolio. For instance, in January 2019, FindAir, a Europe-based company that develops digital systems for asthma and COPD control, launched its commercial smart inhaler device FindAir ONE.

Key players in the market are also focused on receiving certification from regulatory bodies for their novel inhaler devices. For instance, in September 2019, Novartis International AG’s Concept1 inhaler received certification under the new EU Medical Devices Regulation (MDR).

Segmentation

• Global Respiratory Inhaler Market, By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

• Global Respiratory Inhaler Market, By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• Global Respiratory Inhaler Market, By Disease Indication:

• Asthma
• COPD
• Pulmonary Arterial Hypertension
• Others

• Global Respiratory Inhaler Market, By Region:

• North America

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• S.
• Canada
• Europe

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East:

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• GCC
• Israel
• Rest of Middle East
• Africa

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country/Region:

• Central Africa
• South Africa
• North Africa
• Company Profiles

• AstraZeneca plc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments

• Beximco Pharmaceuticals Ltd.
• Boehringer Ingelheim GmbH
• Cipla Ltd.
• GlaxoSmithKline plc.
• Koninklijke Philips N.V.
• Merck & Co., Inc.
• OMRON Healthcare Europe B.V.
• PARI Medical Holding
• Teva Pharmaceutical Industries Ltd.

Contact US:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: [email protected]

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

The post Respiratory Inhalers Market will grow at 12.1% CAGR, to be valued at US$ 32,921.8 Million by 2027, Owing to high prevalence and increasing incidence of respiratory disease are the major factors driving the growth of the market appeared first on Gatorledger.

Respiratory inhaler are sometimes used with a complementary spacer or holding chamber device, in order to reduce deposition in mouth and throat and to alleviate the need for precise synchronization of the start of inhalation with actuation of the device.

Statistics:

The global respiratory inhaler market is estimated to be valued at US$ 32,921.8 Mn in terms of value in 2019 and is expected to reach US$ 46,984.1 Mn by the end of 2027.

Global Respiratory Inhaler Market: Drivers

The increasing adoption of combination therapies such as triple combination therapy for chronic obstructive pulmonary disease (COPD) patients is expected to drive growth of the global respiratory inhaler market over the forecast period. Moreover, rising demand for combined therapies is attributed to benefits offered by combined therapies such as it is more reliable in complex patients, increased efficacy, and easy reimbursement policies related with the therapy.

Global Respiratory Inhaler Market: Opportunities

Moreover, smart inhaler technology is developed to aid patients in keeping a check on their doses and offers various other features. Some devices with smart inhaler technology have the ability to read environment pollution, in terms of air quality, and it alerts the patient about air quality, which can trigger asthma. For instance, Propeller Health, a U.S.-based company started supplementing medicines with this technology. They have connected an inhaler with Bluetooth transmitter to provide connectivity to the smartphone. This technology keeps a track of patient’s asthmatic attack frequency along with possible causes that triggers asthma and it also provide this information to their respective healthcare professional.

Request For Sample Copy Here: https://www.coherentmarketinsights.com/insight/request-sample/227

Global Respiratory Inhaler Market: Restraints

The increasing adoption of respiratory inhaler devices has resulted in high demand for pulmonologist, physicians, and nurses to enable or ensure correct usage of inhalers and nebulizers and to provide adequate training to patients. However, lack of skilled pulmonologist and physicians, especially in developing regions are expected to hamper growth of the market to some extent over the forecast period.

Key Takeaways:

Among product type, metered dose inhaler segment was valued at US$ 22,360.9 Mn in 2018 and is expected to reach US$ 33,825.0 Mn by 2027 exhibiting a CAGR of 4.5% during the forecast period.

Metered-dose inhaler delivers precise dose of medication in aerosol form. The metered-dose inhaler was the first inhaler that was marketed in 1950s and is still the most common inhaler used globally. Moreover, its low cost in comparison to other advanced inhalers such as dry powder inhaler and nebulizer, gives it a competitive advantage, especially in emerging economies such as India, China, and Brazil, where cost is one of the critical factors.

Among technology, manually operated inhaler devices segment held a dominant position in the global respiratory inhaler market in 2018, accounting for 93.1% share in terms of value, followed by digitally operated inhaler devices. Manual inhalers are the most common type of respiratory inhalers. In manual inhalers, medication is stored in pressurized canister in solution form, which also contains a propellant. The most common propellant that is used include hydrofluoroalkane (HFA), which is eco-friendly.

Among disease indication, asthma segment held a dominant position in the global respiratory inhaler market in 2018, accounting for 60.4% share in terms of value, followed by COPD and pulmonary arterial hypertension, respectively.

Moreover, key players are focusing on product launches and approvals for the treatment of asthma is expected to drive growth of the market over the forecast period. For instance, in January 2017, AstraZeneca received the U.S. FDA approval for its Symbicort (budesonide/formoterol fumarate dihydrate), a metered-dose inhaler for the treatment of asthma in pediatric patients aged 6 to 12 years.

Market Trends

In addition, market is witnessing increasing number of R&D about proper usage of inhaler device. For instance, in September 2018, researchers from University of Helsinki, Finland, reported investigation of non-verbal, demonstrational videos as a method of teaching inhaler naïve individuals on how to use a dry powder inhaler (DPI).

Moreover, there is increasing launch of devices to track usage pattern of metered-dose inhalers (MDI) by key players. For instance, in November 2019, Lupin Ltd. launched a device Adhero, which is used for tracking usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.

Get Flat USD 2000 OFF

Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2226

Reasons to Purchase this Report:

Current and future of global Cancer Registry Software Market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

Global Respiratory Inhaler Market: Competitive Landscape

Key players operating in the global respiratory inhaler market include, AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.

Global Respiratory Inhaler Market: Key Developments

Moreover, key players in the market are focused on launching smart inhaler devices to expand their product portfolio. For instance, in January 2019, FindAir, a Europe-based company that develops digital systems for asthma and COPD control, launched its commercial smart inhaler device FindAir ONE.

Key players in the market are also focused on receiving certification from regulatory bodies for their novel inhaler devices. For instance, in September 2019, Novartis International AG’s Concept1 inhaler received certification under the new EU Medical Devices Regulation (MDR).

Segmentation

• Global Respiratory Inhaler Market, By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

• Global Respiratory Inhaler Market, By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• Global Respiratory Inhaler Market, By Disease Indication:

• Asthma
• COPD
• Pulmonary Arterial Hypertension
• Others

• Global Respiratory Inhaler Market, By Region:

• North America

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• S.
• Canada
• Europe

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East:

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country:

• GCC
• Israel
• Rest of Middle East
• Africa

By Product Type:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer
  • Ultrasonic Nebulizer
  • Compressed Air Nebulizer
  • Mesh Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

• By Disease Indication
  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others

By Country/Region:

• Central Africa
• South Africa
• North Africa
• Company Profiles

• AstraZeneca plc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments

• Beximco Pharmaceuticals Ltd.
• Boehringer Ingelheim GmbH
• Cipla Ltd.
• GlaxoSmithKline plc.
• Koninklijke Philips N.V.
• Merck & Co., Inc.
• OMRON Healthcare Europe B.V.
• PARI Medical Holding
• Teva Pharmaceutical Industries Ltd.

Contact US:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: [email protected]

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

The post Respiratory Inhalers Market will grow at 12.1% CAGR, to be valued at US$ 32,921.8 Million by 2027, Owing to high prevalence and increasing incidence of respiratory disease are the major factors driving the growth of the market appeared first on Gatorledger.